Entity

Time filter

Source Type


Tang C.,The General Hospital of Shenyang Military Region | Xue H.,The General Hospital of Shenyang Military Region | Bai C.,Liaoning Medical University | Fu R.,Liaoning Medical University | Wu A.,Liaoning Medical University
Phytomedicine | Year: 2010

Disruption of blood-brain barrier (BBB) and edema formation play a key role in the development of neurological dysfunction after cerebral ischemia. In this study, the effects of Tanshinone IIA (Tan IIA), one of the active ingredients of Salvia miltiorrhiza root, on the BBB and brain edema after transient middle cerebral artery occlusion in rats were examined. Our study demonstrated that Tan IIA reduced brain infarct area, water content in the ischemic hemisphere. Furthermore, Tan IIA significantly decreased BBB permeability to Evans blue, suppressed the expression of intercellular adhesion molecule-1 (ICAM-1), matrix metalloproteinase-9 (MMP-9), inhibited the degradation of tight junction proteins zonula occludens-1 (ZO-1) and Occludin. These results demonstrated that Tan IIA was effective for attenuating the extent of brain edema formation in response to ischemia injury in rats, partly by Tan IIA's protective effect on the BBB. Our results may have implications in the treatment of brain edema in cerebral ischemia. © 2010 Elsevier GmbH. Source


Zhao J.-J.,The General Hospital of Shenyang Military Region | Li H.-Y.,The General Hospital of Shenyang Military Region | Wang D.,The General Hospital of Shenyang Military Region | Yao H.,The General Hospital of Shenyang Military Region | Sun D.-W.,The General Hospital of Shenyang Military Region
Tumor Biology | Year: 2014

This meta-analysis was conducted aiming to evaluate the relationship between abnormal O-6-methylguanine- DNA methyltransferase (MGMT) promoter methylation and the risk of esophageal cancer (EC). A range of electronic databases was searched: Web of Science (1945~2013), the Cochrane Library Database (Issue 12, 2013), MEDLINE (1966~2013), EMBASE (1980~2013), CINAHL (1982~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~2013) without language restrictions. Meta-analysis was performed with the use of the STATA 12.0 software. In the present meta-analysis, 9 clinical cohort studies with a total of 861 EC patients were included. The pooled results revealed that the frequency of MGMT promoter methylation in cancer tissues was significantly higher than in adjacent and normal tissues (cancer tissues vs adjacent tissues, odds ratio (OR)= 6.73, 95 % confidence intervals (95 % CI) 4.75~9.55, P<0.001; cancer tissues vs normal tissues, OR=13.68, 95 % CI 9.47~19.75, P<0.001, respectively). Subgroup analyses by pathological type, ethnicity, and sample size suggested that abnormal MGMT promoter methylation also exhibited a higher frequency in all these subgroups (all P<0.05). Our findings provide empirical evidence that abnormal MGMT promoter methylation may contribute to the risk of EC. Thus, detection ofMGMT promoter methylationmay be utilized as a valuable diagnostic marker for EC. © International Society of Oncology and BioMarkers (ISOBM) 2014 Source

Discover hidden collaborations